NIOSHTIC-2 Publications Search
Tier II mutagenic screening of 13 NIOSH priority compounds, individual compound report, N,N-dimethyl-lacetamide, report no. 27.
Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, Contract 210-78-0026, 1980 Dec; :1-178
The Tier II mutagenic screening of N,N-dimethylacetamide (127195) (DMA) was conducted. The unscheduled DNA synthesis (UDS) assay was conducted with human embryonic intestinal cells, rat liver S9, and 70 to 9366 micrograms per milliliter DMA. A cytogenetic analysis of rat bone marrow cells was performed after in-vivo exposure to 20 or 700 parts per million (ppm) DMA for 7 hours per day for 1 or 5 days. Dominant lethal tests in male rats and sperm abnormality tests in male mice were performed after in-vivo exposure to 20 or 700ppm DMA for 7 hours per day for 5 days. The sex linked recessive lethal test was performed using Drosophila-melanogaster after a 95 minute exposure to 200ppm. DMA produced no increases in UDS, sex linked recessive lethal frequency, abnormal sperm frequency, or rat bone marrow cell DNA aberrations. No effects due to DMA exposure were observed in the dominant lethal assay. The author concludes that DMA showed no mutagenic activity under these test conditions.
NIOSH-Contract; Contract-210-78-0026; Screening-methods; Bioassays; Mutagenesis
Final Contract Report
NTIS Accession No.
National Institute for Occupational Safety and Health
Inveresk Research International Limited, Musselburgh, Scotland
Page last reviewed: May 5, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division